Global Evaluation of the Interstitial Lung Disease (ILD) Diagnostic Pathway in the Post-COVID Era (ILD vMDT)

Study identification

• EU PAS number:
  EUPAS47537
• Study ID:
  47538
• Official title and acronym:
  Global Evaluation of the Interstitial Lung Disease (ILD) Diagnostic Pathway in the Post-COVID Era (ILD vMDT)
• DARWIN EU® study:
  No
• Study countries:
  Argentina

  Australia

  Austria

  Belgium

  Brazil

  Canada

  Chile

  Croatia

  Denmark

  Ecuador

  Egypt

  Finland

  France

  Germany

  Greece

  India

  Indonesia

  Ireland

  Italy

  Japan

  Luxembourg

  Malaysia

  Mexico

  New Zealand

  Norway

  Peru

  Poland

  Portugal

  Romania

  Singapore

  South Africa

  Spain

  Sweden

  Switzerland

  Türkiye

  United Kingdom

  United Kingdom (Northern Ireland)

  United States
• Study description:
  This study aims to identify characteristics of fibrotic interstitial lung disease (ILD) diagnostic practice and the features, strengths and limitations of distanced virtual multi-disciplinary team (vMDT) meetings, and open discussion on the prevalence of post-COVID fibrosis. An on-line survey will be sent via email to dedicated and non-dedicated ILD centres and countries within both mature and expanding economies (featuring a wide range of health systems and health infrastructures) across key global regions. The study will take an inclusive approach, welcoming responses from all countries and participants involved in the diagnosis of ILD.
• Study status:
  Finalised

Research institutions and networks

Networks

Respiratory Effectiveness Group (REG)

Belgium

Denmark

France

Germany

Greece

Hungary

Italy

Netherlands

Spain

Sweden

United Kingdom

Study timelines

Date when funding contract was signed

Planned:19/05/2022

Actual:19/05/2022

Study start date

Planned:20/05/2022

Actual:20/05/2022

Data analysis start date

Planned:23/05/2022

Actual:24/05/2022

Date of interim report, if expected

Planned:23/05/2022

Actual:25/05/2022

Date of final study report

Planned:31/05/2022

Actual:31/05/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable